Trial Profile
Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2020
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- 25 Jun 2014 New trial record